• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by VistaGen Therapeutics Inc.

    2/14/24 4:51:40 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VTGN alert in real time by email
    SC 13G 1 tm243309d26_sc13g.htm SC 13G

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

    VistaGen Therapeutics, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

     

    92840H400

    (CUSIP Number)

     

    December 31, 2023

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    ¨ Rule 13d-1(c)

    ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Continued on following pages

    Page 1 of 7 Pages

     

     

     

     

     

     

    CUSIP NO. 92840H400 Page 2 of 7

     

    CUSIP No.  92840H400
    (1) Names of reporting persons Nantahala Capital Management, LLC
    (2) Check the appropriate box if a member of a group (a)
    (see instructions) (b)
    (3) SEC use only  
    (4) Citizenship or place of organization MA
    Number of shares beneficially owned by each reporting person with:  
    (5) Sole voting power 0
    (6) Shared voting power 2,797,588
    (7) Sole dispositive power 0
    (8) Shared dispositive power 2,797,588
    (9) Aggregate amount beneficially owned by each reporting person 2,797,588
    (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)  
    (11) Percent of class represented by amount in Row (9) 9.9%
    (12) Type of reporting person (see instructions) IA

     

     

     

     

    CUSIP NO. 92840H400 Page 3 of 7

     

    CUSIP No.  92840H400
    (1) Names of reporting persons Wilmot B. Harkey
    (2) Check the appropriate box if a member of a group (a)
    (see instructions) (b)
    (3) SEC use only  
    (4) Citizenship or place of organization USA
    Number of shares beneficially owned by each reporting person with:  
    (5) Sole voting power 0
    (6) Shared voting power 2,797,588
    (7) Sole dispositive power 0
    (8) Shared dispositive power 2,797,588
    (9) Aggregate amount beneficially owned by each reporting person 2,797,588
    (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)  
    (11) Percent of class represented by amount in Row (9) 9.9%
    (12) Type of reporting person (see instructions) HC

     

     

     

     

    CUSIP NO. 92840H400 Page 4 of 7

     

    CUSIP No.  92840H400
    (1) Names of reporting persons Daniel Mack
    (2) Check the appropriate box if a member of a group (a)
    (see instructions) (b)
    (3) SEC use only  
    (4) Citizenship or place of organization USA
    Number of shares beneficially owned by each reporting person with:  
    (5) Sole voting power 0
    (6) Shared voting power 2,797,588
    (7) Sole dispositive power 0
    (8) Shared dispositive power 2,797,588
    (9) Aggregate amount beneficially owned by each reporting person 2,797,588
    (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)  
    (11) Percent of class represented by amount in Row (9) 9.9%
    (12) Type of reporting person (see instructions) HC

     

    Item 1(a). Name of Issuer:
       
      VistaGen Therapeutics, Inc. (the “Issuer”).
       
    Item 1(b). Address of the Issuer's Principal Executive Offices:
       
      343 ALLERTON AVENUE, SOUTH SAN FRANCISCO, CA 94080
       
    Item 2(a). Name of Person Filing
       
      Nantahala Capital Management, LLC (“Nantahala”)
    Wilmot B. Harkey
    Daniel Mack (together the “Reporting Persons”)
       
    Item 2(b). Address of Principal Business Office or, if None, Residence:
       
      130 Main St. 2nd Floor
    New Canaan, CT 06840  
       
    Item 2(c). Citizenship:
       
      Nantahala is a Massachusetts limited liability company.
    Each of Messrs. Harkey and Mack is a citizen of the United States of America.
       
    Item 2(d). Title of Class of Securities:
       
      Common Stock, par value $0.001 per share (the “Shares”).  

     

     

     

     

    CUSIP NO. 92840H400 Page 5 of 7

     

    Item 2(e). CUSIP Number:
       
      92840H400  
       
    Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:  

     

     

    (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

    (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).

     

    (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

     

    (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).

     

    (g) x A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G).

     

    (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

     

    (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

     

    (j) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

    Item 4. Ownership:
       
    Item 4(a).

    Amount Beneficially Owned:

     

    As of December 31, 2023, Nantahala may be deemed to be the beneficial owner of 2,797,588 Shares held by funds and separately managed accounts under its control, and as the managing members of Nantahala, each of Messrs. Harkey and Mack may be deemed to be a beneficial owner of those Shares. The 2,797,588 Shares includes 980,858 Shares which may be acquired by the Reporting Persons within sixty days through the exercise of warrants.

       
    Item 4(b).

    Percent of Class:

     

    As of December 31, 2023, each of the Reporting Persons may be deemed to be the beneficial owner of 9.9% of the total number of Shares outstanding (based upon information provided by the Issuer on Form 10-Q filed November 9, 2023, there were 27,023,038 Shares outstanding in addition to the 980,858 Shares issuable upon the exercise of the warrants.

     

     

     

     

    CUSIP NO. 92840H400 Page 6 of 7

     

    Item 4(c). Number of shares as to which such person has:
       
      Nantahala Capital Management, LLC
       
      (i) Sole power to vote or direct the vote 0
      (ii) Shared power to vote or to direct the vote 2,797,588
      (iii) Sole power to dispose or to direct the disposition of 0
      (iv) Shared power to dispose or to direct the disposition of 2,797,588
           
      Each of Messrs. Harkey and Mack  
       
      (i) Sole power to vote or direct the vote 0
      (ii) Shared power to vote or to direct the vote 2,797,588
      (iii) Sole power to dispose or to direct the disposition of 0
      (iv) Shared power to dispose or to direct the disposition of 2,797,588
           
    Item 5. Ownership of Five Percent or Less of a Class:
       
      This Item 5 is not applicable.
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person:
       
      BLACKWELL PARTNERS LLC - SERIES A, a fund advised by Nantahala, has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of more than five percent of the outstanding shares of common stock beneficially owned by Nantahala reported herein.  
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company:
       
      Each of Messrs. Harkey and Mack is filing this Schedule 13G as a control person in respect of shares beneficially owned by Nantahala, an investment adviser as described in §240.13d-1(b)(1)(ii)(E).  See Item 4(a).
       
    Item 8. Identification and Classification of Members of the Group:
       
      This Item 8 is not applicable.
       
    Item 9. Notice of Dissolution of Group:
       
      This Item 9 is not applicable.
       
    Item 10. Certification:

     

      By signing below each Reporting Person certifies that, to the best of such person's knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.  

     

     

     

     

    CUSIP NO. 92840H400 Page 7 of 7

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete, and correct.

     

     

    Date:  February 14, 2024 NANTAHALA CAPITAL MANAGEMENT, LLC
       
      By: /s/ Taki Vasilakis
      Taki Vasilakis
      Chief Compliance Officer
       
      /s/ Wilmot B. Harkey
      Wilmot B. Harkey
       
      /s/ Daniel Mack
      Daniel Mack

     

     

     

    Get the next $VTGN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VTGN

    DatePrice TargetRatingAnalyst
    12/7/2023$15.00Hold → Buy
    Jefferies
    8/7/2023$30.00Hold → Buy
    Maxim Group
    7/22/2022Outperform → Neutral
    Robert W. Baird
    7/22/2022Buy → Hold
    Jefferies
    7/22/2022Outperform → Mkt Perform
    William Blair
    More analyst ratings

    $VTGN
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Vistagen Therapeutics Inc.

    SCHEDULE 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)

    8/14/25 5:13:28 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Vistagen Therapeutics Inc.

    10-Q - Vistagen Therapeutics, Inc. (0001411685) (Filer)

    8/7/25 4:57:51 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vistagen Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)

    8/7/25 4:56:33 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    VistaGen upgraded by Jefferies with a new price target

    Jefferies upgraded VistaGen from Hold to Buy and set a new price target of $15.00

    12/7/23 6:31:15 AM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VistaGen upgraded by Maxim Group with a new price target

    Maxim Group upgraded VistaGen from Hold to Buy and set a new price target of $30.00

    8/7/23 2:16:37 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VistaGen downgraded by Robert W. Baird

    Robert W. Baird downgraded VistaGen from Outperform to Neutral

    7/22/22 12:22:03 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update

    Topline results of PALISADE-3 Phase 3 Trial of fasedienol for acute treatment of social anxiety disorder expected in the fourth quarter of 2025 PALISADE-4 Phase 3 Trial topline results expected in the first half of 2026 Vistagen continues to advance diverse intranasal pherine pipeline targeting treatments in psychiatry, women's health, and cancer supportive care Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2026 first quarter ended June 30, 2025, and provided a

    8/7/25 4:30:00 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025

    Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on Thursday, August 7, 2025, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2026 first quarter ended June 30, 2025, and provide a corporate update. The conference call is being webcast live, and a link can be found under "Events" in the Investors section of the Company's website. Please click on the webcast link and follow the prompts for registration and access at least 1

    7/31/25 8:30:00 AM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vistagen to Present at the BTIG Virtual Biotechnology Conference

    Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that President and Chief Executive Officer, Shawn Singh, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Tuesday, July 29, at 10 a.m. Eastern Time. The Fireside Chat will be livestreamed for registered investors, and a recording will be available on the BTIG conference portal for conference attendees following the event. If you would like to schedule a one-on-one meeting with Vistagen's management team, please contact yo

    7/24/25 8:30:00 AM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Prince Joshua S. was granted 4,882 shares, increasing direct ownership by 82% to 10,863 units (SEC Form 4)

    4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)

    7/1/25 5:51:38 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Legal Officer Adler Reid G. was granted 7,541 shares, increasing direct ownership by 46% to 24,050 units (SEC Form 4)

    4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)

    7/1/25 5:50:42 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF FINANCIAL OFFICER Anderson Cynthia Lynn was granted 6,617 shares, increasing direct ownership by 107% to 12,801 units (SEC Form 4)

    4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)

    7/1/25 5:49:44 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTGN
    Leadership Updates

    Live Leadership Updates

    View All

    Vistagen Appoints Elissa Cote as Chief Corporate Development Officer

    Accomplished biopharma executive brings nearly 30 years of experience in business development, enterprise strategy, and global partnerships to her role Ms. Cote to help drive the strategic positioning of Vistagen's clinical-stage pipeline, which includes five novel intranasal pherine candidates targeting six highly prevalent and underserved disorders Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Elissa Cote as Chief Corporate Development Officer. In this role, Ms. Cote will lead t

    6/25/25 8:30:00 AM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day

    Vistagen CEO Shawn Singh; The Goldie Hawn Foundation Founder Goldie Hawn; and MindUP students to ring the Nasdaq Closing Bell on October 10, 2024 Vistagen and The Goldie Hawn Foundation join forces to raise awareness around the roles of mindfulness and pioneering neuroscience in mental health Vistagen (NASDAQ:VTGN), a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development of groundbreaking therapies for psychiatric disorders based on nose-to-brain neurocircuitry, and The Goldie Hawn Foundation's MindUP, a neuroscience-based preventative mental health program for youth, along with children from New York City schools utilizing MindUP, will join toget

    10/9/24 8:30:00 AM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vistagen Appoints Cindy Anderson as Chief Financial Officer

    Anderson succeeds Jerrold Dotson who is retiring after a distinguished decade-long career with Vistagen Vistagen (NASDAQ:VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced the appointment of Cindy Anderson as Chief Financial Officer (CFO), effective August 21, 2023. Ms. Anderson will succeed Jerrold Dotson, whose planned retirement was announced in July of this year. "We are delighted to welcome Ms. Anderson, an experienced and highly accomplished finance professional, to our team," said Shawn Singh, Chief Executive Officer of V

    8/22/23 8:30:00 AM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTGN
    Financials

    Live finance-specific insights

    View All

    Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update

    Topline results of PALISADE-3 Phase 3 Trial of fasedienol for acute treatment of social anxiety disorder expected in the fourth quarter of 2025 PALISADE-4 Phase 3 Trial topline results expected in the first half of 2026 Vistagen continues to advance diverse intranasal pherine pipeline targeting treatments in psychiatry, women's health, and cancer supportive care Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2026 first quarter ended June 30, 2025, and provided a

    8/7/25 4:30:00 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025

    Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on Thursday, August 7, 2025, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2026 first quarter ended June 30, 2025, and provide a corporate update. The conference call is being webcast live, and a link can be found under "Events" in the Investors section of the Company's website. Please click on the webcast link and follow the prompts for registration and access at least 1

    7/31/25 8:30:00 AM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

    Topline results of PALISADE-3 Phase 3 Trial of fasedienol for acute treatment of social anxiety disorder expected in the fourth quarter of this year PALISADE-4 Phase 3 Trial topline results expected in the first half of 2026 Company showcases promising clinical-stage pipeline of five novel intranasal pherine candidates targeting six highly prevalent and underserved disorders Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year ended March 31, 2025, and provided a corp

    6/17/25 4:30:00 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Vistagen Therapeutics Inc.

    SC 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)

    11/14/24 5:05:41 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Vistagen Therapeutics Inc.

    SC 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)

    11/14/24 4:19:46 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by VistaGen Therapeutics Inc. (Amendment)

    SC 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)

    2/14/24 6:18:34 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care